Recognizing that Ras/MAP Kinase inhibition alone is likely inadequate, Ross and investigators developed a multi-kinase inhibitor targeting Mek and P13K termed LP-182, which was designed for preferential lymphatic absorption, and were successful in ameliorating the myelofibrosis phenotype as well as improving overall survival in their animal models [96]. This evidence concerns the gene MAP2K7 and myelofibrosis.